Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Aged
Cardiovascular Diseases
/ diagnosis
Diabetes Mellitus, Type 2
/ diagnosis
Disease Progression
Female
Glucagon-Like Peptide-1 Receptor
/ agonists
Humans
Incretins
/ adverse effects
Male
Network Meta-Analysis
Renal Insufficiency, Chronic
/ diagnosis
Risk Assessment
Risk Factors
Sodium-Glucose Transporter 2 Inhibitors
/ adverse effects
Treatment Outcome
Cardiovascular disease
Chronic kidney disease
Diabetes mellitus
GLP-1 receptor agonist
Meta-analysis
Renal outcomes
SGLT2 inhibitors
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
07 01 2021
07 01 2021
Historique:
received:
24
08
2020
accepted:
14
12
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
6
10
2021
Statut:
epublish
Résumé
Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with decreased risk of cardiovascular and renal events in type 2 diabetes mellitus (DM) patients. However, no study to date has compared the effect of SGLT-2 inhibitors with that of GLP-1 RAs in type 2 DM patients with chronic kidney disease (CKD). We herein investigated the benefits of SGLT-2 inhibitors and GLP-1 RAs in CKD patients. We performed a systematic literature search through November 2020. We selected randomized control trials that compared the risk of major adverse cardiovascular events (MACE) and a composite of renal outcomes. We performed a network meta-analysis to compare SGLT-2 inhibitors with GLP-1 RAs indirectly. Risk ratios (RRs) with corresponding 95% confidence intervals (CI) were synthesized. Thirteen studies were selected with a total of 32,949 patients. SGLT-2 inhibitors led to a risk reduction in MACE and renal events (RR [95% CI]; 0.85 [0.75-0.96] and 0.68 [0.59-0.78], respectively). However, GLP-1 RAs did not reduce the risk of cardiovascular or renal adverse events (RR 0.91 [0.80-1.04] and 0.86 [0.72-1.03], respectively). Compared to GLP-1 RAs, SGLT-2 inhibitors did not demonstrate a significant difference in MACE (RR 0.94 [0.78-1.12]), while SGLT-2 inhibitors were associated with a lower risk of renal events compared to GLP-1 RAs (RR 0.79 [0.63-0.99]). A sensitivity analysis revealed that GLP-1 analogues significantly decreased MACE when compared to placebo treatment (RR 0.81 [0.69-0.95]), while exendin-4 analogues did not (RR 1.03 [0.88-1.20]). In patients with type 2 DM and CKD, SGLT-2 inhibitors were associated with a decreased risk of cardiovascular and renal events, but GLP-1 RAs were not. SGLT-2 inhibitors significantly decreased the risk of renal events compared to GLP-1 RAs. Among GLP-1 RAs, GLP-1 analogues showed a positive impact on cardiovascular and renal outcomes, while exendin-4 analogues did not.
Sections du résumé
BACKGROUND
Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with decreased risk of cardiovascular and renal events in type 2 diabetes mellitus (DM) patients. However, no study to date has compared the effect of SGLT-2 inhibitors with that of GLP-1 RAs in type 2 DM patients with chronic kidney disease (CKD). We herein investigated the benefits of SGLT-2 inhibitors and GLP-1 RAs in CKD patients.
METHODS
We performed a systematic literature search through November 2020. We selected randomized control trials that compared the risk of major adverse cardiovascular events (MACE) and a composite of renal outcomes. We performed a network meta-analysis to compare SGLT-2 inhibitors with GLP-1 RAs indirectly. Risk ratios (RRs) with corresponding 95% confidence intervals (CI) were synthesized.
RESULTS
Thirteen studies were selected with a total of 32,949 patients. SGLT-2 inhibitors led to a risk reduction in MACE and renal events (RR [95% CI]; 0.85 [0.75-0.96] and 0.68 [0.59-0.78], respectively). However, GLP-1 RAs did not reduce the risk of cardiovascular or renal adverse events (RR 0.91 [0.80-1.04] and 0.86 [0.72-1.03], respectively). Compared to GLP-1 RAs, SGLT-2 inhibitors did not demonstrate a significant difference in MACE (RR 0.94 [0.78-1.12]), while SGLT-2 inhibitors were associated with a lower risk of renal events compared to GLP-1 RAs (RR 0.79 [0.63-0.99]). A sensitivity analysis revealed that GLP-1 analogues significantly decreased MACE when compared to placebo treatment (RR 0.81 [0.69-0.95]), while exendin-4 analogues did not (RR 1.03 [0.88-1.20]).
CONCLUSIONS
In patients with type 2 DM and CKD, SGLT-2 inhibitors were associated with a decreased risk of cardiovascular and renal events, but GLP-1 RAs were not. SGLT-2 inhibitors significantly decreased the risk of renal events compared to GLP-1 RAs. Among GLP-1 RAs, GLP-1 analogues showed a positive impact on cardiovascular and renal outcomes, while exendin-4 analogues did not.
Identifiants
pubmed: 33413348
doi: 10.1186/s12933-020-01197-z
pii: 10.1186/s12933-020-01197-z
pmc: PMC7792332
doi:
Substances chimiques
GLP1R protein, human
0
Glucagon-Like Peptide-1 Receptor
0
Incretins
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
14Références
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
N Engl J Med. 2020 Oct 8;383(15):1436-1446
pubmed: 32970396
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
Clin Kidney J. 2018 Dec;11(6):749-761
pubmed: 30524708
Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110
pubmed: 31862752
Circulation. 2019 Aug 27;140(9):739-750
pubmed: 31291786
Cardiovasc Diabetol. 2020 Jun 13;19(1):83
pubmed: 32534570
Diabetes Res Clin Pract. 2020 Apr;162:108112
pubmed: 32198123
N Engl J Med. 2017 Sep 28;377(13):1228-1239
pubmed: 28910237
Circulation. 2018 Oct 9;138(15):1537-1550
pubmed: 29941478
Curr Cardiol Rep. 2013 Mar;15(3):340
pubmed: 23338722
Diabetes Care. 2015 Jan;38(1):132-9
pubmed: 25414155
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Horm Metab Res. 2015 Aug;47(9):686-92
pubmed: 25611208
Circulation. 2019 Apr 23;139(17):2022-2031
pubmed: 30786725
Lancet. 2018 Oct 27;392(10157):1519-1529
pubmed: 30291013
Diabetol Int. 2020 Jun 11;11(3):245-251
pubmed: 32802705
Postgrad Med. 2017 Nov;129(8):811-821
pubmed: 28749197
N Engl J Med. 2019 Aug 29;381(9):841-851
pubmed: 31185157
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Am J Kidney Dis. 2020 Jan;75(1 Suppl 1):A6-A7
pubmed: 31704083
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Diabetes Obes Metab. 2020 Dec;22(12):2335-2347
pubmed: 32744354
J Clin Med. 2020 Mar 30;9(4):
pubmed: 32235471
Circulation. 2018 Jan 9;137(2):119-129
pubmed: 28904068
Ann Intern Med. 2015 Jun 2;162(11):777-84
pubmed: 26030634
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Circulation. 2020 Aug 25;142(8):734-747
pubmed: 32795086
Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113
pubmed: 29221659
Clin J Am Soc Nephrol. 2017 May 8;12(5):751-759
pubmed: 28302903
Cardiovasc Diabetol. 2020 Jul 6;19(1):107
pubmed: 32631337
Diab Vasc Dis Res. 2014 Nov;11(6):419-30
pubmed: 25212693
J Hypertens. 2015 Nov;33(11):2185-97
pubmed: 26372321
Indian J Endocrinol Metab. 2013 May;17(3):413-21
pubmed: 23869296
Circulation. 2018 Dec 18;138(25):2908-2918
pubmed: 30566006
Cardiovasc Diabetol. 2020 May 13;19(1):65
pubmed: 32404155
N Engl J Med. 2020 Nov 16;:
pubmed: 33200891
Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785
pubmed: 31422062
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
J Clin Endocrinol Metab. 2012 Jan;97(1):198-207
pubmed: 22013105
Cardiovasc Diabetol. 2020 Jun 10;19(1):74
pubmed: 32522260
N Engl J Med. 2020 Oct 8;383(15):1425-1435
pubmed: 32966714
Lancet. 2019 Jul 13;394(10193):131-138
pubmed: 31189509
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Gastroenterology. 2007 May;132(6):2131-57
pubmed: 17498508
N Engl J Med. 2015 Dec 3;373(23):2247-57
pubmed: 26630143
Kidney Int. 2019 Jan;95(1):178-187
pubmed: 30415941
Rev Endocr Metab Disord. 2014 Sep;15(3):181-7
pubmed: 24811133
Circulation. 2014 Feb 4;129(5):587-97
pubmed: 24334175
Diabetes Res Clin Pract. 2015 Oct;110(1):26-37
pubmed: 26358202
Intern Med. 2020 Jun 15;59(12):1535-1539
pubmed: 32188813
Cardiovasc Diabetol. 2020 Feb 12;19(1):17
pubmed: 32050968
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120